Zobrazeno 1 - 10
of 412
pro vyhledávání: '"S Gail Eckhardt"'
Autor:
Aaron J Scott, Eun-Kee Song, Stacey Bagby, Alicia Purkey, Martin McCarter, Csaba Gajdos, Kevin S Quackenbush, Benjamin Cross, Todd M Pitts, Aik Choon Tan, S Gail Eckhardt, Hubert Fenton, John Arcaroli, Wells A Messersmith
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0187173 (2017)
Dysregulation of the Src pathway has been shown to be important at various stages of cancer. Dasatinib is a potent Src/Abl inhibitor and has demonstrated to have anti-proliferative and anti-invasive activity in many preclinical models. The objective
Externí odkaz:
https://doaj.org/article/ffa9c06bfd5b415295825fb53b2a273e
Autor:
Natalie Julie Serkova, S Gail Eckhardt
Publikováno v:
Frontiers in Oncology, Vol 6 (2016)
For several decades, cytotoxic chemotherapeutic agents were considered the basis of anti-cancer treatment for patients with metastatic tumors. A decrease in tumor burden, assessed by volumetric computed tomography (CT) and magnetic resonance imaging
Externí odkaz:
https://doaj.org/article/ed5f81afecd347e2827b8a524fd5df53
Autor:
Todd M Pitts, Timothy P Newton, Erica L Bradshaw-Pierce, Rebecca Addison, John J Arcaroli, Peter J Klauck, Stacey M Bagby, Stephanie L Hyatt, Alicia Purkey, John J Tentler, Aik Choon Tan, Wells A Messersmith, S Gail Eckhardt, Stephen Leong
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e113037 (2014)
The activation of the MAPK and PI3K/AKT/mTOR pathways is implicated in the majority of cancers. Activating mutations in both of these pathways has been described in colorectal cancer (CRC), thus indicating their potential as therapeutic targets. This
Externí odkaz:
https://doaj.org/article/b1c9a4e1dffc414aa91616e478557aca
Autor:
Erica L Bradshaw-Pierce, Todd M Pitts, Gillian Kulikowski, Heather Selby, Andrea L Merz, Daniel L Gustafson, Natalie J Serkova, S Gail Eckhardt, Colin D Weekes
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e58089 (2013)
The PI3K/AKT/mTOR pathway is frequently dysregulated in cancers and inhibition of mTOR has demonstrated the ability to modulate pro-survival pathways. As such, we sought to determine the ability of the mTOR inhibitor everolimus to potentiate the anti
Externí odkaz:
https://doaj.org/article/5152b740007640cfa69d7e2441e5bd99
Autor:
Nisha Holay, Alexander Somma, Mark Duchow, Milad Soleimani, Anna Capasso, Srividya Kottapalli, Joshua Rios, Uma Giri, Jennifer Diamond, Anna Schreiber, Anthony D. Piscopio, Carla Van Den Berg, S. Gail Eckhardt, Todd A. Triplett
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Histone deacetylase inhibitors (HDACi) are currently being explored for the treatment of both solid and hematological malignancies. Although originally thought to exert cytotoxic responses through tumor-intrinsic mechanisms by increasing expression o
Externí odkaz:
https://doaj.org/article/fb11b1e8367b473a9f32db554b699b48
Autor:
Anna R. Schreiber, Jodi A. Kagihara, Bradley R. Corr, S. Lindsey Davis, Christopher Lieu, Sunnie S. Kim, Antonio Jimeno, D. Ross Camidge, Jud Williams, Amy M. Heim, Anne Martin, John A. DeMattei, Nisha Holay, Todd A. Triplett, S. Gail Eckhardt, Kevin Litwiler, James Winkler, Anthony D. Piscopio, Jennifer R. Diamond
Publikováno v:
Cancers, Vol 16, Iss 1, p 91 (2023)
(1) Background: Histone deacetylases (HDACs) play a critical role in epigenetic signaling in cancer; however, available HDAC inhibitors have limited therapeutic windows and suboptimal pharmacokinetics (PK). This first-in-human phase I dose escalation
Externí odkaz:
https://doaj.org/article/451d3f14506a4c3c96f07402e100bfa1
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 3-15 (2020)
Immunotherapy is a rapidly evolving treatment paradigm that holds promise to provide long-lasting survival benefits for patients with cancer. This promise, however, remains unfulfilled for the majority of patients with gastrointestinal (GI) cancers,
Externí odkaz:
https://doaj.org/article/0ec16298238d4c659aeae02c7d4a6da1
Autor:
Xu Hua, Yongsheng Li, Sairahul R. Pentaparthi, Daniel J. McGrail, Raymond Zou, Li Guo, Aditya Shrawat, Kara M. Cirillo, Qing Li, Akshay Bhat, Min Xu, Dan Qi, Ashok Singh, Francis McGrath, Steven Andrews, Kyaw Lwin Aung, Jishnu Das, Yunyun Zhou, Alessia Lodi, Gordon B. Mills, S. Gail Eckhardt, Marc L. Mendillo, Stefano Tiziani, Erxi Wu, Jason H. Huang, Nidhi Sahni, S. Stephen Yi
Publikováno v:
Cancer Research. 83:59-73
Somatic mutations are a major source of cancer development, and many driver mutations have been identified in protein coding regions. However, the function of mutations located in miRNA and their target binding sites throughout the human genome remai
Autor:
Milad Soleimani, Alexander Somma, Tamer Kaoud, Ria Goyal, Jorge Bustamante, Dennis C. Wylie, Nisha Holay, Agnieszka Looney, Uma Giri, Todd Triplett, Kevin Dalby, Jeanne Kowalski, S. Gail Eckhardt, Carla Van Den Berg
Publikováno v:
Molecular Cancer Therapeutics. 21:1547-1560
The heterogeneity and aggressiveness of triple-negative breast cancer (TNBC) contribute to its early recurrence and metastasis. Despite substantial research to identify effective therapeutic targets, TNBC remains elusive in terms of improving patient
Autor:
S. Gail Eckhardt, Patrick W. Vincent, Shawn M. O'Connell, Robyn Fabrey, Esha Gangolli, Todd M. Pitts, Peter J. Klauck, S. Lindsey Davis, Kelli M. Robertson, Kelsey L. Brunkow, Heather M. Selby, Aik-Choon Tan, John J. Tentler, Lindsey N. Micel
Suppl Figure 3. Immunoblot of Effector Proteins and Markers of Apoptosis in Melanoma Cell Lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::029a0ba35ac9fcdd6c94102286927194
https://doi.org/10.1158/1535-7163.22502620.v1
https://doi.org/10.1158/1535-7163.22502620.v1